Navigation Links
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Date:5/6/2009

ty, non-fatal stroke, non-fatal myocardial infarction, unstable angina, and a subset of revascularization following the initial event. During the course of the study, patients received therapeutic standard of care in addition to high dose Lipitor (atorvastatin).

In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of sPLA2 activity and mass, clinically meaningful and statistically significant reduction in LDL cholesterol, and a reduction in C-reactive protein.

About Acute Coronary Syndrome

Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and heart tracing abnormalities, it is typically classified as a heart attack or myocardial infarction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.¿ Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family - a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes¿ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel¿ upstream steps in the inflammation cascade and have the potential to address a variety of diseases. For more information, please visit

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Amgen (NASDAQ: ... second quarter financial results on Tuesday, July 29, 2014, after ... be followed by a conference call with the investment community ... will be Robert A. Bradway , chairman and chief ... Live audio of the conference call will be ...
(Date:7/24/2014)... , July 24, 2014 IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... Board of Directors.  Mr. Finio has accepted a senior ... the terms of his acceptance of his new position, ... role as Director for IGI Laboratories, Inc.  The effective ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... KOOL ), a leading supplier of innovative products that process ... results for the fiscal third quarter ended March 31, 2012, on ... and Webcast Management will host a conference ... Eastern) to review the fiscal third quarter financial results.  ...
... pharmacy Edens RX ( www.EdensRX.com ) is pleased to announce a ... of May. In recognition of Armed Services Day (May ... the service men and women returning home, military personnel and veterans ... $15 off their order. EdensRX.com is known for both ...
Cached Medicine Technology:ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012 2
(Date:7/24/2014)... a medical device or surgical implant is put inside ... Northwestern University,s Guillermo Ameer, most of the time, that ... , "You will always get an inflammatory response to ... Northwestern,s McCormick School of Engineering and Applied Science and ... "A problem with commonly used plastic materials, in particular, ...
(Date:7/24/2014)... Newark, NJ (PRWEB) July 24, 2014 ... which will give one lucky family a rent-free week ... only until August 3, 2014. Don’t miss your chance ... The sweepstakes is open to all New Jersey residents, ... Horizon BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , ...
(Date:7/24/2014)... IA (PRWEB) July 24, 2014 Members of ... Michael Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, ... Governor appointed him to the Board and that his peers ... “I want to provide the best I can for the ... I am uniquely positioned to provide a special insight to ...
(Date:7/24/2014)... performed during Jewish circumcisions that involves direct oral suction ... type 1 (HSV-1) transmissions documented in infants between 1988 ... Penn Medicine researchers and published online in the ... The reviewers, from Penn,s Center for Evidence-based ... Canada and Israel. , The practiceknown as metzitzah b,pehand ...
(Date:7/24/2014)... 24, 2014 According to market ... Models, Technology Roadmap, Forecasts and Analysis - 2018", ... expected to reach $7.7 billion by 2018 at ... Browse 102 market data tables and 30 figures ... “3D Mapping Market: Global Advancements, Business Models, Technology ...
Breaking Medicine News(10 mins):Health News:Antioxidant biomaterial promotes healing 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... increased risk for life-threatening cardiovascular diseases, people with type ... advised to monitor their blood sugar levels more than ... study. ,Researchers conducted a meta-analysis of 13 previously ... sugar levels and cardiovascular disease. Results showed that blood ...
... of glycosylated hemoglobin, or HA1c, may be an independent ... // and stroke, according to the new research. Two ... control and the development of heart disease and stroke. ... people, investigators found a 21-percent increase in cardiovascular events ...
... tends to be more severe and resistant to medical ... improvement in symptoms when a full range of medical ... patients with asthma were found to have a higher ... compared to patients without asthma. A higher proportion of ...
... used antibiotic, but new research suggests it could be ... study shows patients should not be given erythromycin along ... because it increases the risk of sudden death. ... is any association between the use of erythromycin and ...
... designed to educate parents about allergens and tobacco smoke ... say researchers .More than 900 children with ... least one indoor environmental allergen and lived in low-income ... areas suffer from the disease at a disproportionately high ...
... to a recent study researchers say the antidepressant ... symptoms of fibromyalgia in women . Duloxetine ... // norepinephrine, two of the brain’s neurotransmitters that ... chronic musculoskeletal disorder that is characterized by body ...
Cached Medicine News:
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Straight heavy shafts with 7 mm tying surface. Wide serrated handle, polished finish. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Serrated handle with polished finish. Most popular size or model. Overall length 4 inches....
Medicine Products: